Compare WTTR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | TARS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2017 | 2020 |
| Metric | WTTR | TARS |
|---|---|---|
| Price | $20.17 | $58.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,528,930,000.00 | $451,360,000.00 |
| Revenue This Year | $2.11 | $56.43 |
| Revenue Next Year | $4.94 | $30.19 |
| P/E Ratio | $69.16 | ★ N/A |
| Revenue Growth | 120.79 | ★ 146.71 |
| 52 Week Low | $7.86 | $38.51 |
| 52 Week High | $21.67 | $85.25 |
| Indicator | WTTR | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 45.13 |
| Support Level | $17.60 | $56.05 |
| Resistance Level | $20.27 | $67.14 |
| Average True Range (ATR) | 0.80 | 3.54 |
| MACD | 0.08 | -0.35 |
| Stochastic Oscillator | 60.21 | 23.72 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.